Chargement en cours...
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature
BACKGROUND: Immune checkpoint inhibitors are novel therapies with indications for treating several solid cancers. They are associated with immune-related adverse events, which are generally well tolerated. Though rare, severe side effects may be life-threatening. One such adverse event is Guillain-B...
Enregistré dans:
| Publié dans: | Case Rep Oncol Med |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6893263/ https://ncbi.nlm.nih.gov/pubmed/31885974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5490707 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|